ENTX Stock Forecast: Entera Bio Ltd. Price Predictions for 2026-2027
The 5 Wall Street analysts covering Entera Bio Ltd. hold a median 12-month price target of $9.5 — +187.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 38 of 100 as at 21 Nov 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Entera Bio Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (81): The shares have been drifting up relative to others.
Issuance (20): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
ENTX stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on ENTX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +187.4% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 25 Sept 2026 | Guggenheim | Initiates | Buy | $11 |
| 23 Sept 2026 | LifeSci Capital | Initiates | Outperform | $10 |
| 22 Sept 2026 | Cantor Fitzgerald | Initiates | Overweight | — |
| 18 Sept 2026 | Leerink Partners | Initiates | Outperform | $9.00 |
| 27 Apr 2026 | HC Wainwright & Co. | Maintains | Buy | $10 → $9.00 |
| 9 Feb 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 18 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 11 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 7 Oct 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 27 Sept 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 12 Aug 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 5 June 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 14 May 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 13 May 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 2 Apr 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 11 Dec 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 13 Sept 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 11 Sept 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 8 May 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 4 Apr 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for ENTX.
This page is one stock. Monday covers all of them.
ENTX appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
ENTX vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Entera Bio Ltd. returned +28.1% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
ENTX analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 13703.0×
- Price / book
- 2.1×
- EV / EBITDA
- —
Cheaper than 1% of US stocks
Cheaper than 42% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −20.3%
- Return on assets
- −7.8%
- Dividend yield
- —
Higher than 32% of US stocks
Higher than 29% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Entera Bio Ltd. has a market value of $575.5M and an enterprise value of $310.0M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$17.0M.
Free cash flow in the twelve months to 30 June 2026: −$11.0M.
Entera Bio Ltd. employs 27 people.
Data provided by Twelve Data
ENTX and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at ENTX’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Entera Bio Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about ENTX
What is the ENTX stock price forecast for 2026-2027?
The 5 Wall Street analysts covering Entera Bio Ltd. have a median 12-month price target of $9.5, with estimates ranging from $9 to $11. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is ENTX stock a buy right now?
Of the 5 analysts covering Entera Bio Ltd., 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Entera Bio Ltd. 38 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank ENTX?
As at 21 Nov 2026, Entera Bio Ltd. ranks 38 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Momentum (81 of 100).
Will ENTX stock go up?
No one can know that. What the data says: the median 12-month target from 5 analysts implies +187.4% from the last close, and Ticker Nerd's factor model ranks Entera Bio Ltd. 38 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the ENTX stock forecast for 2030?
No analyst covering Entera Bio Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ENTX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $9 to $11 over the next 12 months.
How has ENTX stock performed over the past year?
Entera Bio Ltd. returned +28.1% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Entera Bio Ltd. do?
Entera Bio Ltd. is a clinical-stage biopharmaceutical company focused on developing orally delivered peptide and protein replacement therapies for serious unmet medical needs. Its work centers on converting complex therapies that are typically injected into mini-tablet formats designed for easier administration and improved patient adherence.
About Entera Bio Ltd.
Entera Bio Ltd. is a clinical-stage biopharmaceutical company focused on developing orally delivered peptide and protein replacement therapies for serious unmet medical needs. Its work centers on converting complex therapies that are typically injected into mini-tablet formats designed for easier administration and improved patient adherence. The company’s technology platform supports oral delivery by stabilizing peptides in the gastrointestinal tract and enhancing absorption into the bloodstream. Entera Bio’s current pipeline includes programs targeting bone, endocrine, and metabolic disorders, with research spanning parathyroid hormone, GLP-1, and GLP-2-based therapies. The company also pursues collaborations and licensing opportunities to advance its oral drug delivery platform across selected therapeutic areas. Headquartered in Jerusalem, Israel, Entera Bio plays a specialized role in the biopharmaceutical market by addressing delivery challenges that limit the use of large-molecule medicines.
CEO Ms. Miranda J. Toledano M.B.A. · 27 employees · Israel · https://enterabio.com